- Advertise
- Contact Editorial
- Editorial Submission Guidelines
- Contact MJH Life Sciences
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Pharmaceutical Executive-09-01-2020
Our Launch-Time Menu
September 16, 2020
From the Editor
40
9
In this September 2020 Product Launch issue of Pharm Exec, we highlight five products, all approved in 2019, and showcase what is now their early brand journey.
Drug Launch: Winning the Evidence Battle
September 14, 2020
Features
40
9
Beyond necessity and nice-to-have, embracing real-world evidence as a true strategic differentiator.
Succession Plan: Skyrizi
September 14, 2020
Features
40
9
Turning to a next-gen psoriasis treatment to help drive future fortunes.
New Standards for First-to-Launch Players
September 14, 2020
Features
40
9
While COVID-19 has shifted some of the rules, research reveals that practice changes were already afoot for market newcomers.
(O)mega Opportunity: Vascepa
September 14, 2020
Features
40
9
Uncovering fish oil derivative’s benefit for heart health.
Educational Mission: Oxbryta
September 14, 2020
Features
40
9
New hope accompanies overdue recognition in sickle cell disease fight.
First in Class: Spravato
September 14, 2020
Features
40
9
Addressing the need for fast-acting therapy in treatment-resistant depression.
One Time for Lifetime: Zolgensma
September 14, 2020
Features
40
9
The world’s most expensive drug put in context.
Biopharma Capital Markets Sizzle in 2020
September 11, 2020
Columns
40
9
The key factors behind the sector’s strong surge in new equity fundraisings.
Key Support for Rare Disease Medicine Scheme
September 11, 2020
Columns
40
9
Orphan drug incentives set to remain in place in Europe.
FDA in Hot Seat on ‘Buy American’ Drug Policy
September 11, 2020
Columns
40
9
Tasked with setting up framework for essential medicine program.
Unlocked Potential — ‘Keying’ in On New-Era Engagement
September 11, 2020
Features
40
9
How adoption of the key account management (KAM) model can help drive pharma’s agility in reaching and influencing a more diverse set of healthcare customers and decision-makers.
Vaccine Supply: Trusting in Blockchain
September 11, 2020
Columns
40
9
As we wait for a COVID-19 vaccine, pharma is looking to blockchain technology to prepare for the major supply-chain obstacles to come.
The Importance of Embracing Diversity
September 11, 2020
Columns
40
9
Creating behavioral change in the pharma workplace.
Staying the Course in Product Launch
September 11, 2020
Features
40
9
Amid pandemic, rely on the fundamentals.
Stepping Out in Oncology
September 11, 2020
Features
40
9
A glimpse inside the latest turn in Liz Barrett’s influential journey as an oncology executive—this time leaving the confines of big pharma to tackle the innovation void in treating urologic cancers.
Sustainable Long-Term Planning
September 11, 2020
Columns
40
9
ESG objectives are integral to long-term biopharma strategy.
Taking Biopharma’s Pulse in a Tough 2020
September 11, 2020
Features
40
9
Assessing COVID-19’s wide and varied impact on pharma and biotech business in the first half of the year, and how it shapes market prospects ahead.
Pharmaceutical Executive, September 2020 Issue (PDF)
September 10, 2020
Issue PDF
40
9
Click the title above for a link to open the Pharmaceutical Executive September 2020 issue in an interactive PDF format.